Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Contracts and grants | 15 | 723 | 30 | 1,367 |
| Total revenues | 22 | 730 | 37 | 1,424 |
| Operating expenses: | ||||
| Research and development | 67,542 | 54,196 | 140,543 | 106,810 |
| General and administrative | 13,103 | 10,391 | 24,552 | 21,211 |
| Total operating expenses | 80,645 | 64,587 | 165,095 | 128,021 |
| Operating loss | (80,623) | (63,857) | (165,058) | (126,597) |
| Investment and other income, net | 7,120 | 7,257 | 12,870 | 16,201 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's R&D?
- Celldex Therapeutics (CLDX) reported R&D of $67.54M in Q2 2026.
- How has Celldex Therapeutics's R&D changed year-over-year?
- Celldex Therapeutics's R&D increased by 24.6% year-over-year, from $54.2M to $67.54M.
- What is the long-term trend for Celldex Therapeutics's R&D?
- Over 4 years (2021 to 2025), Celldex Therapeutics's R&D has grown at a 46.4% compound annual growth rate (CAGR), from $53.31M to $245.07M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Celldex Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude